Overall, both SGLT2-I users and GLP1-RA users appeared to suffer more from comorbidities (hypertension, hyperlipidaemia, retinopathy, neuropathy) compared to SU users, and insulin use was higher in these two groups. This evidence concerns the gene INS and hypertensive disorder.